Press Releases
November 7, 2024
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Additional Formats
October 31, 2024
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Additional Formats
September 9, 2024
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
Additional Formats
September 4, 2024
CytomX Therapeutics to Present at Upcoming September Investor Conferences
Additional Formats
August 8, 2024
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Additional Formats
August 1, 2024
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
Additional Formats
June 18, 2024
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Additional Formats
June 17, 2024
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
Additional Formats
May 22, 2024
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
Additional Formats
May 16, 2024
CytomX Therapeutics Announces New Employment Inducement Grants
Additional Formats
Displaying 1 - 10 of 24